Ciprotab
Ciprotab is a potent, broad-spectrum fluoroquinolone antibiotic containing ciprofloxacin hydrochloride. It works by targeting and inhibiting bacterial DNA gyrase and topoisomerase IV—essential enzymes required for bacterial DNA replication, transcription, repair, and recombination. Because of its targeted bactericidal mechanism, Ciprotab is highly effective against a wide range of Gram-negative and Gram-positive aerobic bacteria.
Primary Medical Indications
Ciprotab is prescribed to treat various moderate to severe bacterial infections, including:
-
Urinary Tract Infections (UTIs): Uncomplicated and complicated cystitis, pyelonephritis (kidney infection), and chronic bacterial prostatitis.
-
Respiratory Tract Infections: Exacerbations of chronic obstructive pulmonary disease (COPD), cystic fibrosis lung infections, and hospital-acquired pneumonia.
-
Gastrointestinal & Abdominal Infections: Typhoid fever (enteric fever), infectious diarrhea, and intra-abdominal infections (used in combination with metronidazole).
-
Skin & Soft Tissue Infections: Infected ulcers, deep-tissue abscesses, and burn wound infections.
-
Bone & Joint Infections: Osteomyelitis and septic arthritis caused by susceptible organisms.
Key Product Specifications & Dosing Forms
| Feature | Specification |
| Active Ingredient | Ciprofloxacin hydrochloride |
| Pharmacological Class | Second-generation Fluoroquinolone Antibiotic |
| Available Formulations | Film-coated oral tablets, IV infusion solution |
| Common Strengths | 250 mg, 500 mg, 750 mg |
| Administration | Take with or without food; drink plenty of fluids to prevent crystalluria. Avoid co-administration with dairy or antacids |
Safety Guidelines & FDA Boxed Warnings
-
Black Box Warning: Fluoroquinolones, including Ciprotab, are associated with an increased risk of tendonitis, tendon rupture (especially the Achilles tendon), peripheral neuropathy, and central nervous system effects.
-
Chelation Interaction: Do not take Ciprotab simultaneously with magnesium/aluminum antacids, iron supplements, sucralfate, or calcium-rich foods/beverages, as they significantly reduce drug absorption. Separate dosing by at least 2 hours before or 6 hours after.
-
Contraindications: Avoid in patients with a history of fluoroquinolone hypersensitivity or myasthenia gravis (may exacerbate muscle weakness).
-
Phototoxicity Risk: May cause severe sunburns; patients should minimize exposure to direct sunlight and artificial UV light during treatment.
Reviews
There are no reviews yet.